中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

79 records (took 0.023 seconds)

    COMPUESTOS DE OXIMA HETEROCICLICOS, UN PROCEDIMIENTO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
    34.
    发明专利
    COMPUESTOS DE OXIMA HETEROCICLICOS, UN PROCEDIMIENTO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN 未知

    公开(公告)号：AR052663A1

    公开(公告)日：2007-03-28

    申请号：ARP060100287

    申请日：2006-01-26

    Applicant: SERVIER LAB

    Inventor： HURTEVENT AURELIE ,  L HELGOUAL CH JEAN-MARTIAL ,  CARATO PASCAL ,  LEBEGUE NICOLAS ,  LECLERC VERONIQUE ,  BERTHELOT PASCAL ,  DACQUET CATHERINE ,  KTORZA ALAIN ,  CAIGNARD DANIEL-HENRI

    IPC: C07D265/36 ,  C07D279/16 ,  A61K31/538 ,  A61P3/10

    Abstract: Compuestos de formula (1) en la cual X representa un átomo de O o de S; A representa una cadena alquileno C1-6, en la que un grupo CH2 puede ser reemplazado, opcionalmente, por un heteroátomo seleccionado entre O o S, o por un grupo NRa (donde Ra representa un átomo de H o alquilo C1-6 lineal o ramificado, o por un grupo fenileno o naftileno; R1 y R2, que pueden ser idénticos o diferentes, representan, cada uno, un átomo de H o alquilo C1-6 lineal o ramificado, alquenilo C2-6 lineal o ramificado, alquinilo C2-6 lineal o ramificado, arilo, arilalquilo C1-6 en el que la parte alquilo puede ser lineal o ramificada, arilalquenilo C2-6 en el que la parte alquenilo puede ser lineal o ramificada, arilalquinilo C2-6 en el que la parte alquinilo puede ser lineal o ramificada, heteroarilo, heteroarilalquilo C1-6 en el que la parte alquilo puede ser lineal o ramificada, heteroarilalquenilo C2-6 en el que la parte alquenilo puede ser lineal o ramificada, heteroarilalquinilo C2-6 en el que la parte alquinilo puede ser lineal o ramificada, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6 en el que la parte alquilo puede ser lineal o ramificada, o polihaloalquilo C1-6 lineal o ramificado; R3 y R4, que pueden ser idénticos o diferentes, representan, cada uno, H o un átomo de halogeno, o un grupo R, OR o NRR', donde R y R', que pueden ser idénticos o diferentes, representan, cada uno, un átomo de H o un alquilo C1-6lineal o ramificado, alquenilo C2-6 lineal o ramificado, alquinilo C2-6 lineal o ramificado, un grupo arilo, arilalquilo C1-6 en el que la parte alquilo puede ser lineal o ramificada, arilalquenilo C2-6 en el que la parte alquenilo puede ser lineal o ramificada, arilalquinilo C2-6 en el que la parte alquinilo puede ser lineal o ramificada, un grupo heteroarilo, heteroarilalquilo C1-6 en el que la parte alquilo puede ser lineal o ramificada, heteroarilalquenilo C2-6en el que la parte alquenilo puede ser lineal o ramificada, heteroarilalquinilo C2-6 en el que la parte alquinilo puede ser lineal o ramificada, cicloalquilo C3-8, cicloalquil C3-8-alquilo c1-6 en el que la parte alquilo puede ser lineal o ramificada, o un grupo polihaloalquilo C1-6 lineal o ramificado, o R3 y R4 forman junto con los átomo de C que los transportan, cuando son transportados por dos átomos de C adyacentes, un anillo que compende 5 o 6 miembros en el anillo, y que pueden contener, opcionalmente, un heteroátomo seleccionado entre O, S y N; B representa alquilo C1-6 lineal o ramificado, alquenilo C2-6 lineal o ramificado, y esos grupos están sustituidos: por un grupo de formula (2) en la cual: R5 representa un grupo de formulas (3) a (6) en los cuales Z representa un átomo de O o de S y R y R', que pueden ser idénticos o diferentes, son tal como se los ha definido precedentemente, y R6 representa un grupo arilo, arilalquilo cuya parte alquilo contiene de 1 a 6 átomos de carbono y puede ser lineal o ramificada, heteroarilo, heteroarilalquilo cuya parte alquilo contiene de 1 a 6 átomos de carbono y puede ser lineal o ramificada, CN, tetrazol, -OR, -NRR', formula (5), (6) o (7), en los cuales Z es tal como se ha definido precedentemente y R y R', que pueden ser idénticos o diferentes, pueden tener las mismas definiciones que se han dado precedentemente, o por un grupo R7 donde R7 representa CN, tetrazol, formula (5), (6) y (8), en los cuales Z es tal como se ha definido precedentemente y R y R', que pueden ser idénticos o diferentes, pueden tener las mismas definiciones que se han dado precedentemente, n representa 0, 1, 2, 3, 4, 5 o 6, y R8 y R9, que pueden ser idénticos o diferentes, representan un átomo de H o un alquilo C1-6 lineal o ramificado, en el que R8 y R9 no pueden representar simultáneamente un átomo de H, o B representa un grupo de formula (2) o un grupo R7 tal como se los ha definido precedentemente, y se entiende que: la oxima R1-C(=N-OR2)- puede tener la configuracion Z o E, se entiende por arilo un grupo fenilo naftilo o bifenilo, en el que esos grupos pueden estar, opcionalmente, parcialmente hidrogenados, se entiende por heteroarilo cualquier grupo aromático mono- o bicíclico que contiene de 5 a 10 miembros en el anillo, y que en el caso de los heteroarilos bicíclicos pueden, opcionalmente, estar parcialmente hidrogenados en uno de los anillos, y que contiene entre 1 y 3 heteroátomos seleccionados entre O, N y S, donde los grupos arilo y heteroarilo definidos de esa forma, pueden ser substituidos, opcionalmente, por 1 a 3 grupos que pueden ser idénticos o diferentes, seleccionados entre alquilo C1-6 lineal o ramificado, polihaloalquilo C1-6 lineal o ramificado, alcoxi C1-6 lineal o ramificado, hidroxi, carboxi, formilo, acilo C1-6 lineal o ramificado, aroilo, NRbRc (en el cual Rb y Rc, que pueden ser idénticos o diferentes, representan un átomo de H, alquilo C1-6 lineal o ramificado, arilo o heteroarilo), éster, amido, nitro, ciano y átomos de halogeno, a sus enantiomeros y diastereoisomeros, y también sus sales de adicion con un ácido o con una base farmacéuticamente aceptables.

    35.
    发明专利
    未知

    公开(公告)号：DE602004003751D1

    公开(公告)日：2007-02-01

    申请号：DE602004003751

    申请日：2004-07-27

    Applicant: SERVIER LAB

    Inventor： LECLERC VERONIQUE ,  PAILLOUX SYLVIE ,  CARATO PASCAL ,  INTROVIGNE CARINE ,  LEBEGUE NICOLAS ,  BERTHELOT PASCAL ,  DACQUET CATHERINE ,  BOUTIN JEAN ALBERT ,  CAIGNARD DANIEL HENRI ,  RENARD PIERRE

    IPC: A61K31/428 ,  C07D235/26 ,  A61K31/426 ,  A61K31/427 ,  A61P1/04 ,  A61P1/18 ,  A61P3/06 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P13/04 ,  A61P13/12 ,  A61P15/00 ,  A61P17/06 ,  A61P19/10 ,  A61P21/04 ,  A61P25/28 ,  A61P27/02 ,  A61P35/00 ,  C07D235/12 ,  C07D277/68 ,  C07D417/10 ,  C07D417/12

    Abstract: Benzoxazole, benzothiazole or indole oxime derivatives (I) (including analogs with the benzo ring replaced by pyridine, pyrazine, pyrimidine or pyridazine) are new. Benzoxazole, benzothiazole or indole oxime derivatives of formula (I) (including analogs with the benzo ring replaced by pyridine, pyrazine, pyrimidine or pyridazine), and their enantiomers, diastereomers and salts are new. [Image] X : O, S, CH 2 or CHR' 2>; R 1>, R 2>H, alkyl, aryl, aralkyl, aryloxy, aralkoxy, alkoxy, OH, NH 2 or mono- or dialkylamino; or R 1> + R 2>=O, =S or =NH; R' 2>group forming an additional bond with R 2>; A : 1-6C alkylene (optionally having one CH 2 replaced by O, S, NRa', phenylene or naphthylene); Ra' : H or alkyl; R 3>, R 4>H, halo, R, OR or NRR'; or R 3> + R 4>group forming an ortho-fused 5- or 6-membered ring (optionally containing an O, S or N heteroatom); R, R', R 5>, R 6>H, alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heteroaralkynyl, cycloalkyl, cycloalkylalkyl or polyhaloalkyl; D : benzene ring (in which case X is other than CHR' 2>); or a pyridine, pyrazine, pyrimidine or pyridazine ring; B : alkyl or alkenyl, both substituted by -CHR 7>R 8> or by R 9>; or -CHR 7>R 8> or R 9>; R 7>-C(Z)OR, -C(Z)NRR', -N(R)C(Z)R' or -N(R)C(Z)OR'; Z : O or S; R 8>aryl, aralkyl, heteroaryl, heteroaralkyl, CN, tetrazole, OR, NRR', -N(R)C(Z)R' or -N(R)C(Z)OR'; R 9>CN, tetrazole, -N(R)C(Z)R', -N(R)C(Z)OR' or -O(CH 2) n-CR 1> 0>R 1> 1>-COOR; n : 0-6; R 1> 0>, R 1> 1>H or alkyl, but not both H; aryl moieties : phenyl, naphthyl or biphenyl (all optionally partially hydrogenated and optionally substituted by 1-3 alkyl, polyhaloalkyl, alkoxy, OH, COOH, CHO, NRaRb, ester, amido, NO 2, CN or halo groups); heteroaryl moieties : 5-10 membered mono- or bicyclic aryl (where one ring is optionally partially hydrogenated in the case of bicyclic systems) containing 1-3 O, S and/or N heteroatom(s) and optionally substituted as for aryl; Rb, Rc : H, alkyl, aryl or heteroaryl; the oxime group -C(R 6>)=NOR 5> has E- or Z-configuration; alkyl moieties have 1-6C, alkenyl or alkynyl moieties 2-6C and cycloalkyl moieties 3-8C. Independent claims are included for: (1) preparation method of (I); and (2) new ketone intermediates of formula (V). [Image] ACTIVITY : Antidiabetic; Antilipemic; Cardiant; Nephrotropic; Ophthalmological; Antipsoriatic; Gynecological; Nootropic; Osteopathic; Antiinflammatory; Antiarteriosclerotic; Anorectic; Cytostatic. In tests in ob/ob mice, oral administration of 10 mg/kg of methyl 3-(4-(2-(6-((methoxyimino)-(phenyl)-methyl)-2-oxo-1,3-benzothiazol-3(2H)-yl)-ethoxy)-phenyl)-2-(2,2,2-trifluoroethoxy)-propanoate (Ia) twice per day for 4 days reduced blood sugar levels by 51% and reduced the weight gain by 80% in comparison with controls, whereas analogous administration of rosiglitazone reduced blood sugar levels by 61% but increased the weight gain by 33% in comparison with controls. MECHANISM OF ACTION : Aldose Reductase Inhibitor; Angiogenesis Inhibitor.

    Novel heterocyclic oxime derivatives, method for preparing same and use thereof as hypoglycaemic or hypolipidemic agents
    37.
    发明专利
    Novel heterocyclic oxime derivatives, method for preparing same and use thereof as hypoglycaemic or hypolipidemic agents 未知

    公开(公告)号：AU2006208811A1

    公开(公告)日：2006-08-03

    申请号：AU2006208811

    申请日：2006-01-26

    Applicant: SERVIER LAB

    Inventor： LECLERC VERONIQUE ,  HURTEVENT ,  DACQUET CATHERINE ,  LEBEGUE NICOLAS ,  KTORZA ALAIN ,  CAIGNARD DANIEL-HENRI ,  CARATO PASCAL ,  CH JEAN-MARTIAL L HELGOUAL ,  BERTHELOT PASCAL

    IPC: C07D279/16 ,  A61K31/538 ,  A61K31/5415 ,  A61P3/06 ,  A61P3/10 ,  C07D265/36

    Abstract: Heterocyclic oxime derivatives (I), their enantiomers, diastereomers and their acid or basic addition salts are new. Heterocyclic oxime derivatives of formula (I), their enantiomers, diastereomers and their acid or basic addition salts are new. X : O or S; A : 1-6C alkyl (where CH 2 can be replaced by heteroatom (O or S), NR a or a phenyl or naphthyl group); R aH or 1-6C alkyl; R 1>, R 2>, R, R1 : H, 1-6C ((hetero)aryl)alkyl, 2-6C ((hetero)aryl)alkenyl, 2-6C ((hetero)aryl)alkynyl, (hetero)aryl, 3-8C cycloalkyl-1-6C alkyl or polyhalo-1-6C alkyl; either R 3>, R 4>H, halo, R, OR or NRR1; or -C-R 3>-R 4>-C- : 5-6 membered ring (containing heteroatom (O, S or N); B 1>1-6C alkyl, 2-6C alkenyl (both optionally substituted by -CHR 5>R 6> or R 7>), -CHR 5>R 6> or R 7>; R 5>-C(=Z)-OR, -C(=Z)-NRR1, -N(R)-C(=Z)-R1 or -N(R)-C(=Z)-OR1; Z : O or S; R 6>(hetero)aryl, (hetero)aryl-1-6C alkyl, CN, tetrazole, OR, NRR1, -N(R)-C(=Z)-R1, -N(R)-C(=Z)-OR1 or -N(R)-C(=Z)-R; R 7>CN, tetrazole, -N(R)-C(=Z)-R1, -N(R)-C(=Z)-OR1 or -O-(CH 2) n-C(R 8>R 9>)-COOR; n : 1-6; and R 8>, R 9>H or 1-6C alkyl. Provided that both R 8> and R 9> are not simultaneously H. Provided that: the oxime R 1>-C(=N-OR 2>)- can be the Z or E configuration; the aryl are phenyl, naphthyl or biphenyl, which can be partially hydrogenated; the heteroaryl are 5-10 membered mono or bicylic aromatic, where the bicyclics can partially be hydrogenated, and containing 1-3 heteroatom (O, N or S); the (hetero)aryl are optionally substituted by 1-3 of 1-6C (polyhalo)alkyl, 1-6C alkoxy, OH, carboxy, 1-6C alkoxycarbonyl, 1-6C acyloxy, formyl, 1-6C acyl, aryl, NR bR c, amido, nitro, CN or halo, where R b, R c are H, 1-6C alkyl or (hetero)aryl. Independent claims are included for: (1) the preparations of (I); (2) a composition (X) comprising (I) an antioxidant agent. [Image] ACTIVITY : Antidiabetic; Antilipemic; Analgesic; Antianginal; Cardiant; Vasotropic; Cardiovascular-Gen.; Nephrotropic; Ophthalmological; Antipsoriatic; Gynecological; Osteopathic; Gastrointestinal-Gen.; Antiinflammatory; Antiarteriosclerotic; Anorectic; Anabolic; Eating-Disorders-Gen.; Neuroprotective; Cytostatic; Endocrine-Gen.; Neuroleptic. The antidiabetic and hypolipidemic effect of (I) was tested in female mouse. The results showed that (I) exhibited a very good capacity to reduce the glycemia compared with the effects obtained with Rosiglitazone. MECHANISM OF ACTION : Angiogenesis inhibitor.

    NEW HETEROCYCLIC OXIME COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    38.
    发明专利
    NEW HETEROCYCLIC OXIME COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM 未知

    公开(公告)号：HK1071748A1

    公开(公告)日：2005-07-29

    申请号：HK05104493

    申请日：2005-05-30

    Applicant: SERVIER LAB

    Inventor： LECLERC VERONIQUE ,  PAILLOUX SYLVIE ,  CARATO PASCAL ,  INTROVIGNE CARINE ,  LEBEGUE NICOLAS ,  BERTHELOT PASCAL ,  DACQUET CATHERINE ,  BOUTIN JEAN ALBERT ,  CAIGNARD DANIEL-HENRI ,  RENARD PIERRE

    IPC: C07D235/26 ,  A61K20090101 ,  A61K31/426 ,  A61K31/427 ,  A61P20090101 ,  A61P1/04 ,  A61P1/18 ,  A61P3/06 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P13/04 ,  A61P13/12 ,  A61P15/00 ,  A61P17/06 ,  A61P19/10 ,  A61P21/04 ,  A61P25/28 ,  A61P27/02 ,  A61P35/00 ,  C07D20090101 ,  C07D235/12 ,  C07D277/68 ,  C07D417/10 ,  C07D417/12

    Abstract: Benzoxazole, benzothiazole or indole oxime derivatives (I) (including analogs with the benzo ring replaced by pyridine, pyrazine, pyrimidine or pyridazine) are new. Benzoxazole, benzothiazole or indole oxime derivatives of formula (I) (including analogs with the benzo ring replaced by pyridine, pyrazine, pyrimidine or pyridazine), and their enantiomers, diastereomers and salts are new. [Image] X : O, S, CH 2 or CHR' 2>; R 1>, R 2>H, alkyl, aryl, aralkyl, aryloxy, aralkoxy, alkoxy, OH, NH 2 or mono- or dialkylamino; or R 1> + R 2>=O, =S or =NH; R' 2>group forming an additional bond with R 2>; A : 1-6C alkylene (optionally having one CH 2 replaced by O, S, NRa', phenylene or naphthylene); Ra' : H or alkyl; R 3>, R 4>H, halo, R, OR or NRR'; or R 3> + R 4>group forming an ortho-fused 5- or 6-membered ring (optionally containing an O, S or N heteroatom); R, R', R 5>, R 6>H, alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heteroaralkynyl, cycloalkyl, cycloalkylalkyl or polyhaloalkyl; D : benzene ring (in which case X is other than CHR' 2>); or a pyridine, pyrazine, pyrimidine or pyridazine ring; B : alkyl or alkenyl, both substituted by -CHR 7>R 8> or by R 9>; or -CHR 7>R 8> or R 9>; R 7>-C(Z)OR, -C(Z)NRR', -N(R)C(Z)R' or -N(R)C(Z)OR'; Z : O or S; R 8>aryl, aralkyl, heteroaryl, heteroaralkyl, CN, tetrazole, OR, NRR', -N(R)C(Z)R' or -N(R)C(Z)OR'; R 9>CN, tetrazole, -N(R)C(Z)R', -N(R)C(Z)OR' or -O(CH 2) n-CR 1> 0>R 1> 1>-COOR; n : 0-6; R 1> 0>, R 1> 1>H or alkyl, but not both H; aryl moieties : phenyl, naphthyl or biphenyl (all optionally partially hydrogenated and optionally substituted by 1-3 alkyl, polyhaloalkyl, alkoxy, OH, COOH, CHO, NRaRb, ester, amido, NO 2, CN or halo groups); heteroaryl moieties : 5-10 membered mono- or bicyclic aryl (where one ring is optionally partially hydrogenated in the case of bicyclic systems) containing 1-3 O, S and/or N heteroatom(s) and optionally substituted as for aryl; Rb, Rc : H, alkyl, aryl or heteroaryl; the oxime group -C(R 6>)=NOR 5> has E- or Z-configuration; alkyl moieties have 1-6C, alkenyl or alkynyl moieties 2-6C and cycloalkyl moieties 3-8C. Independent claims are included for: (1) preparation method of (I); and (2) new ketone intermediates of formula (V). [Image] ACTIVITY : Antidiabetic; Antilipemic; Cardiant; Nephrotropic; Ophthalmological; Antipsoriatic; Gynecological; Nootropic; Osteopathic; Antiinflammatory; Antiarteriosclerotic; Anorectic; Cytostatic. In tests in ob/ob mice, oral administration of 10 mg/kg of methyl 3-(4-(2-(6-((methoxyimino)-(phenyl)-methyl)-2-oxo-1,3-benzothiazol-3(2H)-yl)-ethoxy)-phenyl)-2-(2,2,2-trifluoroethoxy)-propanoate (Ia) twice per day for 4 days reduced blood sugar levels by 51% and reduced the weight gain by 80% in comparison with controls, whereas analogous administration of rosiglitazone reduced blood sugar levels by 61% but increased the weight gain by 33% in comparison with controls. MECHANISM OF ACTION : Aldose Reductase Inhibitor; Angiogenesis Inhibitor.

    New heterocyclic oxime compounds, a process for their preparation and pharmaceutical compositions containing them
    40.
    发明专利
    New heterocyclic oxime compounds, a process for their preparation and pharmaceutical compositions containing them 未知

    公开(公告)号：AU2004203454A1

    公开(公告)日：2005-02-17

    申请号：AU2004203454

    申请日：2004-07-28

    Applicant: SERVIER LAB

    Inventor： RENARD PIERRE ,  CAIGNARD DANIEL-HENRI ,  BOUTIN JEAN ALBERT ,  DACQUET CATHERINE ,  BERTHELOT PASCAL ,  LEBEGUE NICOLAS ,  INTROVIGNE CARINE ,  CARATO PASCAL ,  PAILLOUX SYLVIE ,  LECLERC VERONIQUE

    IPC: C07D235/26 ,  A61K31/426 ,  A61K31/427 ,  A61P1/04 ,  A61P1/18 ,  A61P3/06 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P13/04 ,  A61P13/12 ,  A61P15/00 ,  A61P17/06 ,  A61P19/10 ,  A61P21/04 ,  A61P25/28 ,  A61P27/02 ,  A61P35/00 ,  C07D235/12 ,  C07D277/68 ,  C07D417/10 ,  C07D417/12 ,  C07D263/54 ,  C07D209/14 ,  A61K31/428 ,  A61K31/423 ,  C07D407/12 ,  C07D513/04 ,  C07D498/04 ,  C07D487/04 ,  C07D471/04 ,  A61P3/04 ,  C07D277/62

    Abstract: Benzoxazole, benzothiazole or indole oxime derivatives (I) (including analogs with the benzo ring replaced by pyridine, pyrazine, pyrimidine or pyridazine) are new. Benzoxazole, benzothiazole or indole oxime derivatives of formula (I) (including analogs with the benzo ring replaced by pyridine, pyrazine, pyrimidine or pyridazine), and their enantiomers, diastereomers and salts are new. [Image] X : O, S, CH 2 or CHR' 2>; R 1>, R 2>H, alkyl, aryl, aralkyl, aryloxy, aralkoxy, alkoxy, OH, NH 2 or mono- or dialkylamino; or R 1> + R 2>=O, =S or =NH; R' 2>group forming an additional bond with R 2>; A : 1-6C alkylene (optionally having one CH 2 replaced by O, S, NRa', phenylene or naphthylene); Ra' : H or alkyl; R 3>, R 4>H, halo, R, OR or NRR'; or R 3> + R 4>group forming an ortho-fused 5- or 6-membered ring (optionally containing an O, S or N heteroatom); R, R', R 5>, R 6>H, alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heteroaralkynyl, cycloalkyl, cycloalkylalkyl or polyhaloalkyl; D : benzene ring (in which case X is other than CHR' 2>); or a pyridine, pyrazine, pyrimidine or pyridazine ring; B : alkyl or alkenyl, both substituted by -CHR 7>R 8> or by R 9>; or -CHR 7>R 8> or R 9>; R 7>-C(Z)OR, -C(Z)NRR', -N(R)C(Z)R' or -N(R)C(Z)OR'; Z : O or S; R 8>aryl, aralkyl, heteroaryl, heteroaralkyl, CN, tetrazole, OR, NRR', -N(R)C(Z)R' or -N(R)C(Z)OR'; R 9>CN, tetrazole, -N(R)C(Z)R', -N(R)C(Z)OR' or -O(CH 2) n-CR 1> 0>R 1> 1>-COOR; n : 0-6; R 1> 0>, R 1> 1>H or alkyl, but not both H; aryl moieties : phenyl, naphthyl or biphenyl (all optionally partially hydrogenated and optionally substituted by 1-3 alkyl, polyhaloalkyl, alkoxy, OH, COOH, CHO, NRaRb, ester, amido, NO 2, CN or halo groups); heteroaryl moieties : 5-10 membered mono- or bicyclic aryl (where one ring is optionally partially hydrogenated in the case of bicyclic systems) containing 1-3 O, S and/or N heteroatom(s) and optionally substituted as for aryl; Rb, Rc : H, alkyl, aryl or heteroaryl; the oxime group -C(R 6>)=NOR 5> has E- or Z-configuration; alkyl moieties have 1-6C, alkenyl or alkynyl moieties 2-6C and cycloalkyl moieties 3-8C. Independent claims are included for: (1) preparation method of (I); and (2) new ketone intermediates of formula (V). [Image] ACTIVITY : Antidiabetic; Antilipemic; Cardiant; Nephrotropic; Ophthalmological; Antipsoriatic; Gynecological; Nootropic; Osteopathic; Antiinflammatory; Antiarteriosclerotic; Anorectic; Cytostatic. In tests in ob/ob mice, oral administration of 10 mg/kg of methyl 3-(4-(2-(6-((methoxyimino)-(phenyl)-methyl)-2-oxo-1,3-benzothiazol-3(2H)-yl)-ethoxy)-phenyl)-2-(2,2,2-trifluoroethoxy)-propanoate (Ia) twice per day for 4 days reduced blood sugar levels by 51% and reduced the weight gain by 80% in comparison with controls, whereas analogous administration of rosiglitazone reduced blood sugar levels by 61% but increased the weight gain by 33% in comparison with controls. MECHANISM OF ACTION : Aldose Reductase Inhibitor; Angiogenesis Inhibitor.

Patent Agency Ranking